A Director at Portola Pharma is Exercising Options

Yesterday it was reported that a Director at Portola Pharma (PTLAResearch Report), Henry Ward Wolff, exercised options to buy 5,000 PTLA shares at $5.10 a share, for a total transaction value of $25.5K. The options were close to expired and Henry Ward Wolff retained stocks.

This recent transaction increases Henry Ward Wolff’s holding in the company by 46.44% to a total of $519.3K.

See today’s analyst top recommended stocks >>

Based on Portola Pharma’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $15.3 million and GAAP net loss of $88.55 million. In comparison, last year the company earned revenue of $9.8 million and had a GAAP net loss of $91.78 million. The Company has a Price to Book ratio of 24.8231. Currently, Portola Pharma has an average volume of 672.5K.

Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $40.50, reflecting a 23.0% upside. Four different firms, including Citigroup and Morgan Stanley, currently also have a Buy rating on the stock.

The insider sentiment on Portola Pharma has been positive according to 47 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. It offers Andexxa, and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

Leave a Reply

Your email address will not be published. Required fields are marked *